Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients

NCT02774278 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02774278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02774278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
June 30, 2009
Enrollment
264 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer